SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2010 - 2026)
SELLAS Life Sciences (SLS) reported Net Income towards Common Stockholders of -$8.4 million for Q1 2026, down 44.62% year-over-year from -$15.2 million in Q1 2025, and down 9.78% quarter-over-quarter from -$7.7 million in Q4 2025.
SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$8.4 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$8.4 million, down 44.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.5 million (down 8.59% YoY), and the FY2025 annual result was -$26.9 million, up 13.01% from the prior year.
- Net Income towards Common Stockholders declined to -$8.4 million in Q1 2026 per SLS's latest filing, from -$7.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$5.8 million in Q1 2025 and troughed at -$16.7 million in Q1 2022.
- A 5-year average of -$8.6 million and a median of -$8.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 596.42% in 2022, then surged 39.23% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.4 million in 2022, then climbed by 13.87% to -$8.1 million in 2023, then grew by 17.2% to -$6.7 million in 2024, then declined by 13.67% to -$7.7 million in 2025, then retreated by 9.78% to -$8.4 million in 2026.
- Business Quant data shows SLS's Net Income towards Common Stockholders at -$8.4 million in Q1 2026, -$7.7 million in Q4 2025, and -$6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -8.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.41 Mn |
| Dec 31, 2025 | -7.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -6.60 Mn |
| Sep 30, 2021 | -7.09 Mn |
| Jun 30, 2021 | -4.61 Mn |